Boundless Bio, Inc. (BOLD)
(Delayed Data from NSDQ)
$8.59 USD
-0.51 (-5.60%)
Updated May 10, 2024 04:00 PM ET
After-Market: $8.56 -0.03 (-0.35%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
View All Zacks #1 Ranked Stocks
Brokerage Reports
0 items in cart
[BOLD]
Reports for Purchase
Showing records 41 - 60 ( 89 total )
Industry: Medical - Biomedical and Genetics
3Q18 Corporate Update: One Big Step Forward, Two Small Steps Back
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Price: 25.00
Industry: Medical - Biomedical and Genetics
3Q18 Financials; Registration Discussions with Regulators up Ahead
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Price: 25.00
Industry: Medical - Biomedical and Genetics
Assuming Management Has Some Significant BD Aspirations to Stomach a Secondary Offering at $29; Lowering Target to $33
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Price: 25.00
Industry: Medical - Biomedical and Genetics
Positive Dose Level 2, Follow Up Data and Epidemiology Insights a Plus for MTM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Price: 25.00
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Price: 25.00
Industry: Medical - Biomedical and Genetics
ASPIRO Update - A One-and-Done Option for XLMTM Is Potentially Upon Us
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Price: 25.00
Industry: Medical - Biomedical and Genetics
Price: 25.00
Industry: Unclassified
Pre-ASH Catalyst Calendar For Stocks Under Coverage
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Price: 50.00
Industry: Unclassified
RMAT Nice to Have; However, the Street Awaits Clarity on CN and Pompe Programs
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Price: 25.00
Industry: Unclassified
Price: 50.00
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Price: 25.00
Industry: Unclassified
2Q18 Financials; XLMT Continues to Exceed Expectations
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Price: 25.00
Industry: Unclassified
Compelling Clinical Update From ASPIRO Balanced by the Delay in the Pompe Program
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Price: 25.00
Industry: Unclassified
XLMTM Update: Durable Improvements for MTM, Muscle Biopsy Data Next in Q3
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Price: 25.00
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Price: 25.00
Industry: Unclassified
AT132 Living Up to Its Promise, But More Gaps to Fill; Target Revised to $40 From $37
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Price: 25.00
Industry: Unclassified
Week Ahead
Provider: WEDBUSH SECURITIES INC.
Price: 10.00
Industry: Unclassified
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Price: 25.00
Industry: Unclassified
CN Might Cause Some Near Term Jaundice in the Stock; We Await Clinical Updates During 2H
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Price: 25.00
Industry: Unclassified
1Q18; First Crigler Patient Data, Update for MTM Next Week, Pushing Pompe
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Price: 25.00